Subject of the day
XBRANE.ST
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. The company also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane, a daratumumab biosimilar targeting CD38 for the treatment of multiple myeloma. The company has a strategic partnership with JOINN Biologics US Inc. to provide customized development services for Xdarzane, Xbrane´s biosimilar candidate referencing Darzalex. The company was incorporated in 2008 and is headquartered in Solna, Sweden.
| Line | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 |
|---|---|---|---|---|
| Revenue | $65.90M | $93.24M | $39.90M | $9.10M |
| Gross profit | $61.11M | $52.94M | $39.91M | $1.68M |
| Operating income | $8.91M | $27.66M | -$7.71M | -$24.66M |
| Net income | -$53.20M | $8.16M | $169.59M | -$26.48M |
| Diluted EPS | -0.03 | 0.01 | 0.11 | -0.06 |
| Free cash flow | $76.61M | -$92.66M | -$113.99M | -$67.56M |
| CapEx | -$17.30M | -$24.02M | -$48.93M | — |
$9.72
▲ +0.14 (+1.5%)
| 52w hi | $36.78 |
|---|---|
| 52w lo | $5.66 |
| Vol | 24.56K |
| As of | Aug 13 |
Our score +0.13
| Short | -0.10 |
|---|---|
| Medium | +0.24 |
| Long | +0.36 |
computed 2026-08-13
Xbrane Biopharma AB (publ)
Healthcare · Biotechnology
| Market cap | $196.99M |
|---|---|
| Enterprise value | $214.50M |
| Trailing P/E | — |
| Forward P/E | 478.00x |
| EV / EBITDA | -3.50x |
| P / S (ttm) | 2.36x |
| Profit margin | -90.0% |
| Return on equity | -16.0% |
| Revenue growth | +17.1% |
| Earnings growth | — |
| Debt / equity | 11.82 |
| Beta vs SPX | 0.42 |
|---|---|
| Corr SPX | 0.07 |
| Annual vol | 95.6% |
| Annual ret | +4.0% |
| Sharpe | 0.04 |
| Max DD | -84.7% |
Window: 504 trading days (490 obs)
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.27 | |
| Sector | +0.12 | |
| Technical | +0.00 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-08-13
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Aug 13 | $9.72 | $9.76 | $9.44 | — | 24.56K |
| Aug 12 | $9.58 | $9.84 | $9.56 | $9.72 | 21.35K |
| Aug 11 | $10.15 | $10.15 | $9.50 | $9.58 | 39.88K |
| Aug 10 | $10.05 | $10.15 | $9.96 | $10.15 | 10.67K |
| Aug 7 | $9.98 | $10.10 | $9.86 | $10.00 | 20.76K |